Biofrontera Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Biofrontera Stock Summary

Biofrontera competes with Shuttle Pharmaceuticals, Akanda Corp, China Pharma, Sunshine Biopharma, and Petros Pharmaceuticals. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.

Biofrontera Key Financial Ratios

Biofrontera Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biofrontera's current stock value. Our valuation model uses many indicators to compare Biofrontera value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biofrontera competition to find correlations between indicators driving Biofrontera's intrinsic value. More Info.Biofrontera is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Biofrontera's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biofrontera's earnings, one of the primary drivers of an investment's value.

Biofrontera Systematic Risk

Today, most investors in Biofrontera Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biofrontera's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biofrontera growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Biofrontera help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biofrontera. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biofrontera based on widely used predictive technical indicators. In general, we focus on analyzing Biofrontera Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biofrontera's daily price indicators and compare them against related drivers.

When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.